Through this agreement, BioWisdom gains access to the data within Asterand’s proprietary Target Evaluator database. The database consists of quantitative human gene expression profiles that chart the expression topography of more than 2,500 commercially relevant gene transcripts across a panel of 72 human tissues. These profiles are systematically generated using high quality human RNA and a sensitive RT-PCR protocol.
BioWisdom will harmonize the data with its software solutions enabling the information to be combined with other public and private sources or utilized independently as raw data or assertional meta data. The harmonized Asterand data are available as an entire dataset or sub-sets of selected targets and tissues.
Martyn Coombs, CEO of Asterand, said: The combination of Asterand’s human gene expression profile data with BioWisdom’s ontology software solutions will be a powerful tool in the discovery of new pathway specific therapeutic strategies, biomarker applications and potential side-effect liabilities for drug candidates that interact with specific targets.